Tiger Brokers

BUZZ-FibroGen rises after company begins mid-stage study for prostate cancer therapy

Reuters
Sep 25
BUZZ-FibroGen rises after company begins mid-stage study for prostate cancer therapy

** Shares of drug developer FibroGen FGEN.O rise 2.3% to $12.25

** Company says it has began testing its experimental therapy, FG-3246, in patients with metastatic castration-resistant prostate cancer in a mid-stage study

** The condition is an advanced stage of prostate cancer in which the cancer has spread to distant parts of the body and continues to grow and progress despite hormonal therapy aimed at lowering testosterone

** The trial will also evaluate how well FG-3180 works as a diagnostic and predictive PET imaging agent, which uses the same CD46-targeted antibody as FG-3246

** Company expects results from the interim analysis of a 75-patient mid-stage study in the second half of 2026

** Including session's moves, stock up 7.5% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10